Article
KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm.
Blood advances - 8 Sept 2026
Navarro-Navarro Paula, Fernández-Giménez Carlos M, García-Montero Andrés C, Álvarez-Twose Iván, Sánchez-Muñoz Laura, Henriques Ana, Pérez-Pons Alba, González-Tablas María, Teodosio Cristina, González-González María, Matarraz Sergio, López Antonio, Barcena Paloma, Colado Enrique, Esteve Jordi, Senent Mª Leonor, González-López Óscar, Mollejo Manuela, Morales-Cabeza Cristina, Jara-Acevedo María, Orfao Alberto
Abstract excerpt
ABSTRACT: In 5% to 15% of patients with systemic mastocytosis (SM), SM coexists with an associated hematological neoplasm (AHN). Most patients with SM-AHN harbor a KIT mutation, mainly KIT p.D816V, together with other AHN-related genetic alterations; however, limited data exist about the frequency and clinical impact of the coexistence of both types of genetic alterations in the same vs distinct bone marrow (BM)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.